456例住院精神分裂症患者代谢综合征的调查(3)
 |
| 第1页 |
参见附件。
[7] De Hert M，Van Winkel R，Van Eyck D，et al. Prevalence of diabetes，metabolic syndrome and metabolic abnormalites in schizophrenia over the course of the illness across-sectional study [J]. ClinPract Epidemol Ment Health，2006，2： 14.
[8] Correll CU， Frederickson AM， Kane J，et al. M etabolicsyndrome and the risk of coronary heart disease in 367 patients treated with second - generation antipsychotic drugs [J]. J C linPsychiat，2006，67(4)：575- 583.
[9] 喻东山，高振忠.精神科合理用药手册[M].南京：江苏科学技术出版社，2005：104.
[10] Gianfrancesco FD，Grogg AL，Mahmoud RA，et al. Differentional effects of risperidone，olanzapine，clozapine and conventional antipsychoticson type 2 diabetes：findings from a large health plan： database [J]. Year Book of Psychiatry＆Applied Mental Health，2004：343- 344.
[11] Conhen，D. Diabetes mellitus during olanzapine and quetiapine treatment in Japan [J]. J Clin Psychiatry，2005，66(2)：265-266.
[12] Allison DB，Mentore JL，Heo M，et al. Antipsychotic-induced weight gain： a comprehensive research synthesis [J]. Am J Psychiatry，1999， 156(11)：1686-1696.
[13] Keck PE Jr，McElory SL. Aripiprazole：a partial dopamine D2 receptoragonist antipsychotic [J]. Expert OpinInvestig Drugs，2003，12(3)：655-662.
[14] Correll CU，Frederickson AM，Kane JM，et al. Does an tipsychotic polypharmacy increase the risk for metablic syndrome [J]. Schizophres，2007，89(3)：91-100.
(收稿日期：2012-05-14 本文编辑：冯 婕)
您现在查看是摘要介绍页，详见PDF附件(2767kb)。